Document is current
Any future updates will be listed below
-
Authors
Menghoum, Nassiba
Badii, Maria Chiara
Leroy, Martin
Parra, Marie
Roy, Clotilde
Lejeune, Sibille
Vancraeynest, David
Pasquet, Agnes
Brito, Dulce
Casadei, Barbara
Depoix, Christophe
Filippatos, Gerasimos
Gruson, Damien
Edelmann, Frank
Ferreira, Vanessa M.
Lhommel, Renaud
Mahmod, Masliza
Neubauer, Stefan
Persu, Alexandre
Piechnik, Stefan
Hellenkamp, Kristian
Ikonomidis, Ignatios
Krakowiak, Bartosz
Pieske, Burkert
Pieske-Kraigher, Elisabeth
Pinto, Fausto
Ponikowski, Piotr
Senni, Michele
Trochu, Jean-Noël
Van Overstraeten, Nancy
Wachter, Rolf
Gerber, Bernhard L.
Balligand, Jean-Luc
Beauloye, Christophe
Pouleur, Anne-Catherine
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03197350 at ClinicalTrials.govnct02599480 at ClinicalTrials.govDocuments that mention this clinical trial
Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction
https://doi.org/10.1186/s12933-025-02688-7
Documents that mention this clinical trial
New drugs in preclinical and early stage clinical development in the treatment of heart failure
https://doi.org/10.1080/13543784.2019.1551357
Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction
https://doi.org/10.1186/s12933-025-02688-7
-
Funding
Funding for this research was provided by:
Fondation Saint-Luc
- License Information
-
More Information
Article History
Received: 17 November 2024
Accepted: 13 March 2025
First Online: 22 March 2025
Declarations
:
: The study was approved by the Institutional Review Board of the Cliniques universitaires Saint-Luc, Université Catholique de Louvain, and all participants gave written consent to participate in the study.
: Not applicable.
: The authors declare no competing interests.
